The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab (C), fluorouracil (F), and cisplatin (P) alone or with docetaxel (D) for recurrent/metastatic (RM) head and neck cancer (HNSCC): First analysis of AIO trial # 1108.
Ulrich Keilholz
Research Funding - Merck KGaA; Sanofi
Thomas Christoph Gauler
Research Funding - Merck KGaA; Sanofi
Andreas Dietz
Research Funding - Merck KGaA
Viktor Gruenwald
Research Funding - Merck KGaA
Jan Stoehlmacher-Williams
Research Funding - Merck KGaA
Stephan Knipping
No relevant relationships to disclose
Michael Schroeder
No relevant relationships to disclose
Orlando Guntinas-Lichius
Research Funding - Merck KGaA
Norbert Frickhofen
No relevant relationships to disclose
Hans Walter Lindemann
No relevant relationships to disclose
Rainer Fietkau
No relevant relationships to disclose
Boris Haxel
No relevant relationships to disclose
Christian Junghanss
No relevant relationships to disclose
Georg Maschmeyer
No relevant relationships to disclose
Matthias Zipfel
No relevant relationships to disclose
Peter Martus
No relevant relationships to disclose
Maren Kristina Knoedler
Research Funding - Merck KGaA